These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9329355)

  • 21. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults.
    Cenci MC; Conceição FL; Soares DV; Spina LD; Brasil RR; Lobo PM; Michmacher E; Vaisman M
    Metabolism; 2008 Jan; 57(1):121-9. PubMed ID: 18078869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle.
    Bramnert M; Segerlantz M; Laurila E; Daugaard JR; Manhem P; Groop L
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1455-63. PubMed ID: 12679422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.
    Johannsson G; Mårin P; Lönn L; Ottosson M; Stenlöf K; Björntorp P; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1997 Mar; 82(3):727-34. PubMed ID: 9062473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.
    Biller BM; Sesmilo G; Baum HB; Hayden D; Schoenfeld D; Klibanski A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):970-6. PubMed ID: 10720025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of glucose and lipid metabolism and bone mineralization in patients with growth hormone deficiency with and without long-term growth hormone replacement.
    Roemmler J; Kuenkler M; Schneider HJ; Dieterle C; Schopohl J
    Metabolism; 2010 Mar; 59(3):350-8. PubMed ID: 19800640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults.
    Ezzat S; Fear S; Gaillard RC; Gayle C; Landy H; Marcovitz S; Mattioni T; Nussey S; Rees A; Svanberg E
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2725-33. PubMed ID: 12050241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition.
    Jørgensen JO; Vahl N; Hansen TB; Thuesen L; Hagen C; Christiansen JS
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):681-8. PubMed ID: 9039333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women.
    Burman P; Johansson AG; Siegbahn A; Vessby B; Karlsson FA
    J Clin Endocrinol Metab; 1997 Feb; 82(2):550-5. PubMed ID: 9024252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations in body composition and fat distribution in growth hormone-deficient prepubertal children during growth hormone therapy.
    Roemmich JN; Huerta MG; Sundaresan SM; Rogol AD
    Metabolism; 2001 May; 50(5):537-47. PubMed ID: 11319714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of short-term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerotic markers in hypopituitary patients with growth hormone deficiency.
    Benedini S; Dalle Carbonare L; Albiger N; Scanarini M; Bilora F; Petrobelli F; Giannini S; Mantero F; Scaroni C
    Horm Metab Res; 2006 Jan; 38(1):16-21. PubMed ID: 16477535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose metabolism and visceral fat in GH deficient adults: two years of GH-replacement.
    Spina LD; Soares DV; Brasil RR; Lobo PM; Lúcia Conceição F; Vaisman M
    Pituitary; 2004; 7(3):123-129. PubMed ID: 16328562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial.
    Franco C; Brandberg J; Lönn L; Andersson B; Bengtsson BA; Johannsson G
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1466-74. PubMed ID: 15598680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.
    Ahn CW; Kim CS; Nam JH; Kim HJ; Nam JS; Park JS; Kang ES; Cha BS; Lim SK; Kim KR; Lee HC; Huh KB
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):444-9. PubMed ID: 16584518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole body and regional soft tissue changes in growth hormone deficient adults after one year of growth hormone treatment: a double-blind, randomized, placebo-controlled study.
    Hansen TB; Vahl N; Jørgensen JO; Christiansen JS; Hagen C
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):689-96. PubMed ID: 8736270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
    Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
    Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of growth hormone and 17beta-oestradiol treatment on metabolism and body composition in girls with Turner syndrome.
    Gravholt CH; Hjerrild BE; Naeraa RW; Engbaek F; Mosekilde L; Christiansen JS
    Clin Endocrinol (Oxf); 2005 May; 62(5):616-22. PubMed ID: 15853835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function.
    Newman CB; Frisch KA; Rosenzweig B; Roubenoff R; Rey M; Kidder T; Kong Y; Pursnani A; Sedlis SP; Schwartzbard A; Kleinberg DL
    J Clin Endocrinol Metab; 2011 Jan; 96(1):122-32. PubMed ID: 20926529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.